NASDAQ:OVID - US6904691010 - Common Stock
The current stock price of OVID is 1.14 USD. In the past month the price increased by 116.11%. In the past year, price increased by 0.88%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.6 | 366.65B | ||
AMGN | AMGEN INC | 13.23 | 155.30B | ||
GILD | GILEAD SCIENCES INC | 14.75 | 141.64B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.96 | 99.72B | ||
REGN | REGENERON PHARMACEUTICALS | 12.54 | 60.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.15B | ||
ARGX | ARGENX SE - ADR | 73.07 | 41.45B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.23 | 36.69B | ||
INSM | INSMED INC | N/A | 27.12B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
NTRA | NATERA INC | N/A | 22.30B | ||
BIIB | BIOGEN INC | 8.52 | 19.99B |
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The firm is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. The company is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. The company develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. The company also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
OVID THERAPEUTICS INC
441 Ninth Avenue, 14Th Floor
New York City NEW YORK 10036 US
CEO: Jeremy M. Levin
Employees: 23
Phone: 12127764381
The current stock price of OVID is 1.14 USD. The price increased by 10.68% in the last trading session.
The exchange symbol of OVID THERAPEUTICS INC is OVID and it is listed on the Nasdaq exchange.
OVID stock is listed on the Nasdaq exchange.
12 analysts have analysed OVID and the average price target is 3.47 USD. This implies a price increase of 204.21% is expected in the next year compared to the current price of 1.14. Check the OVID THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OVID THERAPEUTICS INC (OVID) has a market capitalization of 81.07M USD. This makes OVID a Micro Cap stock.
OVID THERAPEUTICS INC (OVID) currently has 23 employees.
The Revenue of OVID THERAPEUTICS INC (OVID) is expected to grow by 581.37% in the next year. Check the estimates tab for more information on the OVID EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OVID does not pay a dividend.
OVID THERAPEUTICS INC (OVID) will report earnings on 2025-11-10, before the market open.
OVID THERAPEUTICS INC (OVID) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.53).
The outstanding short interest for OVID THERAPEUTICS INC (OVID) is 2.71% of its float. Check the ownership tab for more information on the OVID short interest.
ChartMill assigns a technical rating of 9 / 10 to OVID. When comparing the yearly performance of all stocks, OVID is one of the better performing stocks in the market, outperforming 98.35% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to OVID. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months OVID reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -23.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -30.58% | ||
ROE | -42.13% | ||
Debt/Equity | 0 |
12 analysts have analysed OVID and the average price target is 3.47 USD. This implies a price increase of 204.21% is expected in the next year compared to the current price of 1.14.
For the next year, analysts expect an EPS growth of -43.56% and a revenue growth 581.37% for OVID